Pandorum and AGC have teamed up to produce Pandorum's flagship exosome product Kuragenx, which they refer to as a 'liquid cornea'. Pandorum says that Kuragenx has demonstrated promising results in the preclinical...
Phase III exPDite-2 trial follows completion and discussion of Phase I trial data with US FDA under Regenerative Medicine Advanced Therapy (RMAT) designation exPDite-2 is a randomized, sham surgery-controlled double-blind trial assessing...
European Exosome maker EXO Biologics and its CDMO subsidiary, ExoXpert, say they're the first European CDMO specializing in exosomes to receive Good Manufacturing Practice (GMP) certification. In addition, EXO Biologics says it...
Celularity Inc. (Nasdaq: CELU), a regenerative and cellular medicine company, announced that it received recommendation letters from the FDA's Tissue Reference Group (TRG), regarding its Natalin and Acelagraft™ products confirming that each product “appears...
BioRestorative Therapies, a regenerative medicine company focused on stem cell-based therapies, has announced that the FDA has cleared its Investigational New Drug (“IND”) application for BRTX-100, a novel cell-based therapeutic engineered to...
Japan is reportedly in the final stages of approving the first induced pluripotent stem cell (iPS cell) treatment for inclusion in its national healthcare system. Approval would position Japan among the first...
South Korea's MEDIPOST, Inc., a company developing stem cell-based therapeutics, has announced the appointment of five senior executives, which they say will bring decades of expertise in biologics and cell & gene...
